title: [Should Angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis?].
abstract: It is well established that long-term administration of angiotensin-converting enzyme (ACE) inhibitors has a favorable effect in patients with chronic heart failure and dilated cardiomyopathy. However, less information is available on patients whose left ventricular ejection fraction normalizes after an episode of systolic dysfunction secondary to acute myocarditis. We followed 35 patients who were diagnosed at our center between 1987 and 1995 with acute myocarditis and an ejection fraction<45%. All were taking ACE inhibitors. After 34 (23) months of follow-up, the left ventricular ejection fraction was >50% in all 35 patients. Treatment with ACE inhibitors was discontinued in 15 of the 35 patients, while the other 20 continued ACE inhibitor therapy. After 3 years of follow-up, no death had occurred, but the incidence of new episodes of heart failure with a left ventricular ejection fraction<45% was higher in patients who stopped taking ACE inhibitors (33% vs 5%, P=.064), and their ejection fraction was lower (47 [12%] vs 57 [11%], P=.002). These results suggest that ACE inhibitors should be continued over the long term in these patients.
authors.affiliation: Servicio de Cardiología, Hospital Reina Sofía, Córdoba, Spain. manuelp.anguita.sspa@juntadeandalucia.es
authors.forename: Manuel
authors.initials: M
authors.lastname: Anguita-Sánchez
authors.forename: Juan C
authors.initials: JC
authors.lastname: Castillo-Domínguez
authors.forename: Dolores
authors.initials: D
authors.lastname: Mesa-Rubio
authors.forename: Martín
authors.initials: M
authors.lastname: Ruiz-Ortiz
authors.forename: Amador
authors.initials: A
authors.lastname: López-Granados
authors.forename: José
authors.initials: J
authors.lastname: Suárez de Lezo
mesh_terms: D000208:Acute Disease; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009205:Myocarditis / Q000188:drug therapy*; D013318:Stroke Volume / Q000502:physiology*; D013997:Time Factors; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors